Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EHA 2022 | Safety and efficacy of MB-106 for the treatment of R/R FL

Mazyar Shadman • 10 Jun 2022
EHA 2022
Follicular Lymphoma Lymphoma Non-Hodgkin Lymphoma CAR-T MB-106

Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center, Seattle, WA, talks on the safety and efficacy of MB-106, a third-generation CD20-targeted CAR T-Cell therapy for the treatment of relapsed/refractory (R/R) follicular lymphoma (FL). This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Mazyar Shadman

Expanding the CAR platform for NHL 11:30
Expanding the CAR platform for NHL
Catherine Bollard et al. • 28 Sep 2025
The role of zanubrutinib in CLL treatment and its relative efficacy compared to other BTKis 2:10
The role of zanubrutinib in CLL treatment and its relative efficacy compared to other BTKis
Mazyar Shadman • 13 Sep 2025
The development of resource-restricted guidelines for the diagnosis and management of CLL 4:43
The development of resource-restricted guidelines for the diagnosis and management of CLL
Mazyar Shadman • 13 Sep 2025
Rare symptoms and complications in CLL 1:22
Rare symptoms and complications in CLL
Mazyar Shadman • 13 Sep 2025

Related Videos

Long-term follow-up results from ELM-2: odronextamab in R/R FL 8:08
Long-term follow-up results from ELM-2: odronextamab in R/R FL
Gottfried von Keudell • 18 Sep 2025
The efficacy of glofitamab in patients with heavily pre-treated R/R MCL 1:24
The efficacy of glofitamab in patients with heavily pre-treated R/R MCL
Tycel Phillips • 5 Sep 2025
Bringing clinical trials to the community: current approaches at Sarah Cannon Research Institute 1:01
Bringing clinical trials to the community: current approaches at Sarah Cannon Research Institute
Krish Patel • 4 Sep 2025
Bispecifics and CAR T-cell therapy in lymphoma: sequencing strategies and considerations 1:52
Bispecifics and CAR T-cell therapy in lymphoma: sequencing strategies and considerations
Tycel Phillips • 5 Sep 2025
The content of VJHemOnc is intended for healthcare professionals